1-3 of 3
Ulrich J.M. Mey, MD
Close
Sort by
Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Eva Kimby, MD professor, Stephanie Rondeau, MSc, Anna Vanazzi, MD, Bjorn Ostenstad, MD PhD, Ulrich J.M. Mey, MD, Daniel Rauch, MD, Björn E Wahlin, MD PhD, Felicitas Hitz, MD, Micaela Hernberg, MD, Ann-Sofie Johansson, MD, Peter de Nully Brown, MD PhD, Hans Hagberg, MD PhD, Andres J.M. Ferreri, MD professor, Andreas Lohri, MD professor, Urban Novak, MD, Thilo Zander, MD, Hanne Bersvendsen, MD, Mario Bergetzi, MD, Walter Mingrone, MD, Fatime Krasniqi, MD PhD, Stefan Dirnhofer, MD professor, Hanne Hawle, MD, Simona Berardi, PhD, Michele Ghielmini, MD professor, Emanuele Zucca
Journal: Blood
Blood (2016) 128 (22): 1099.
https://doi.org/10.1182/blood.V128.22.1099.1099
Published: 2016
Journal Articles

High Dose Chemotherapy with Autologous Stem Cell Transplantation in Malignant Lymphoma - A Single Center Experience.

Ulrich J.M. Mey, MD, Vandana Jha, Marcus Gorschlueter, MD, John W. Strehl, MD, Tilman Sauerbruch, MD, Axel G. Glasmacher, MD, Ingo G.H. Schmidt-Wolf, MD
Journal: Blood
Blood (2005) 106 (11): 5483.
https://doi.org/10.1182/blood.V106.11.5483.5483
Published: 2005
Journal Articles

A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Ulrich J.M. Mey, MD, John W. Strehl, MD, Katjana S. Orlopp, MD, Dimitri Flieger, MD, J. Birkmann, MD, Anthony Ho, MD, U. Kaiser, MD, Andreas Neubauer, MD, Axel G. Glasmacher, MD, Ingo G.H. Schmidt-Wolf, MD
Journal: Blood
Blood (2004) 104 (11): 4618.
https://doi.org/10.1182/blood.V104.11.4618.4618
Published: 2004